Showing results (251-260 of 344) with videos related to

Sort By:
Pageof 35
Circulation Research|April 5, 2003
HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genesBirgit Assmus, Carmen Urbich, Alexandra Aicher, et al.
Die Pharmazie|June 18, 2009
Aphyllin, the first isoferulic acid glycoside and other phenolics from Tamarix aphylla flowersM A M Nawwar, S A M Hussein, N A Ayoub, et al.
Annals of Hematology|August 9, 2013
Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factorsM Kripp, A Willer, C Schmidt, et al.
European Journal of Radiology|December 21, 2013
Whole-body CT for lymphoma staging: feasibility of halving radiation dose and risk by iterative image reconstructionM Meyer, S A Klein, G Brix, et al.
The International Journal of Biological Markers|April 1, 1994
Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseasesP Stieber, H Dienemann, U Hasholzner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2007
Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcomeClaudia D Baldus, Peter Martus, Thomas Burmeister, et al.
Genes, Chromosomes & Cancer|December 18, 2001
Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumorsCarl W Miller, Takayuki Ikezoe, Utz Krug, et al.
Annals of Hematology|August 20, 2018
Course of colonization by multidrug-resistant organisms after allogeneic hematopoietic cell transplantationD Heidenreich, S Kreil, M Jawhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adultsClaudia D Baldus, Thomas Burmeister, Peter Martus, et al.
BMC Palliative Care|January 3, 2024
Treatment of agitation in terminally ill patients with intranasal midazolam versus subcutaneous midazolam: study protocol for a randomised controlled open-label monocentric trial (MinTU Study)Hanna Hirschinger, Evelyn Jaeger, Stefanie Nittka, et al.
Pageof 35